Apolipoprotein epsilon 3 alleles are associated with indicators of neuronal resilience

BMC Medicine

Sue T Griffin³  Frederick Boop²  Robert E Mrak¹  Orwa Aboud³ 

[1]Department of Pathology, University of Toledo Health Sciences Campus, 3000 Arlington Avenue, Toledo, OH 43614, USA

[2]Department of Neurosurgery, University of Tennessee Health Sciences Center, 50 N Dunlap St, Memphis, TN 38163 USA

[3]Department of Neurobiology and Developmental Sciences, University of Arkansas College of Medicine, 4300 Markham Street, Little Rock, AR 72205, USA

关键词: TUNEL;    synaptophysin;    phosphorylated tau;    neuroinflammation;    interleukin-1;    epilepsy;    DNA damage;    APOE genotype;    Alzheimer disease;    Amyloid beta (Aβ);   

Others  :  1126267
DOI  :  10.1186/1741-7015-10-35

 received in 2011-12-11, accepted in 2012-04-13,  发布年份 2012

【 摘 要 】

Background

Epilepsy is associated with precocious development of Alzheimer-type neuropathological changes, including appearance of senile plaques, neuronal loss and glial activation. As inheritance of APOE ε4 allele(s) is reported to favor this outcome, we sought to investigate neuronal and glial responses that differ according to APOE genotype. With an eye toward defining ways in which APOE ε3 alleles may foster neuronal well-being in epilepsy and/or APOE ε4 alleles exacerbate neuronal decline, neuronal and glial characteristics were studied in temporal lobectomy specimens from epilepsy patients of either APOE ε4,4 or APOE ε3,3 genotype.

Methods

Tissue and/or cellular expressions of interleukin-1 alpha (IL-1α), apolipoprotein E (ApoE), amyloid β (Aβ) precursor protein (βAPP), synaptophysin, phosphorylated tau, and Aβ were determined in frozen and paraffin-embedded tissues from 52 APOE ε3,3 and 7 APOE ε4,4 (0.25 to 71 years) epilepsy patients, and 5 neurologically normal patients using Western blot, RT-PCR, and fluorescence immunohistochemistry.

Results

Tissue levels of IL-1α were elevated in patients of both APOE ε3,3 and APOE ε4,4 genotypes, and this elevation was apparent as an increase in the number of activated microglia per neuron (APOE ε3,3 vs APOE ε4,4 = 3.7 ± 1.2 vs 1.5 ± 0.4; P < 0.05). This, together with increases in βAPP and ApoE, was associated with apparent neuronal sparing in that APOE ε4,4 genotype was associated with smaller neuron size (APOE ε4,4 vs APOE ε3,3 = 173 ± 27 vs 356 ± 45; P ≤ 0.01) and greater DNA damage (APOE ε4,4 vs APOE ε3,3 = 67 ± 10 vs 39 ± 2; P = 0.01). 3) Aβ plaques were noted at early ages in our epilepsy patients, regardless of APOE genotype (APOE ε4,4 age 10; APOE ε3,3 age 17).

Conclusions

Our findings of neuronal and glial events, which correlate with lesser neuronal DNA damage and larger, more robust neurons in epilepsy patients of APOE ε3,3 genotype compared to APOE ε4,4 genotype carriers, are consistent with the idea that the APOE ε3,3 genotype better protects neurons subjected to the hyperexcitability of epilepsy and thus confers less risk of AD (Alzheimer's disease).

Please see related article: http://www.biomedcentral.com/1741-7015/10/36 webcite

【 授权许可】

   
2012 Aboud et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Gouras GK, Relkin NR, Sweeney D, Munoz DG, Mackenzie IR, Gandy S: Increased apolipoprotein E epsilon 4 in epilepsy with senile plaques. Ann Neurol 1997, 41:402-404.
• [2]Mackenzie IR, Miller LA: Senile plaques in temporal lobe epilepsy. Acta Neuropathol (Berl) 1994, 87:504-510.
• [3]Griffin WS, Yeralan O, Sheng JG, Boop FA, Mrak RE, Rovnaghi CR, Burnett BA, Feoktistova A, Van Eldik LJ: Overexpression of the neurotrophic cytokine S100 beta in human temporal lobe epilepsy. J Neurochem 1995, 65:228-233.
• [4]Sheng JG, Boop FA, Mrak RE, Griffin WS: Increased neuronal beta-amyloid precursor protein expression in human temporal lobe epilepsy: association with interleukin-1 alpha immunoreactivity. J Neurochem 1994, 63:1872-1879.
• [5]Gahring LC, White HS, Skradski SL, Carlson NG, Rogers SW: Interleukin-1alpha in the brain is induced by audiogenic seizure. Neurobiol Dis 1997, 3:263-269.
• [6]Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, Araoz C: Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989, 86:7611-7615.
• [7]Barger SW, Harmon AD: Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997, 388:878-881.
• [8]Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ, Griffin WS: In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging 1996, 17:761-766.
• [9]Liu L, Aboud O, Jones RA, Mrak RE, Griffin ST, Barger SW: Apolipoprotein E expression is elevated by interleukin 1 and other interleukin 1-induced factors. J Neuroinflammation 2011, 8:175. BioMed Central Full Text
• [10]Barger SW, DeWall KM, Liu L, Mrak RE, Griffin WS: Relationships between expression of apolipoprotein E and beta-amyloid precursor protein are altered in proximity to Alzheimer beta-amyloid plaques: potential explanations from cell culture studies. J Neuropathol Exp Neurol 2008, 67:773-783.
• [11]Teasdale GM, Murray GD, Nicoll JA: The association between APOE epsilon4, age and outcome after head injury: a prospective cohort study. Brain 2005, 128:2556-2561.
• [12]Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H: The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ 2006, 2006:re1.
• [13]Li Y, Wang J, Sheng JG, Liu L, Barger SW, Jones RA, Van Eldik LJ, Mrak RE, Griffin WS: S100 beta increases levels of beta-amyloid precursor protein and its encoding mRNA in rat neuronal cultures. J Neurochem 1998, 71:1421-1428.
• [14]Braak E, Strotkamp B, Braak H: Parvalbumin-immunoreactive structures in the hippocampus of the human adult. Cell Tissue Res 1991, 264:33-48.
• [15]Vezzani A, Balosso S, Ravizza T: The role of cytokines in the pathophysiology of epilepsy. Brain Behav Immun 2008, 22:797-803.
• [16]Miller MA, Conley Y, Scanlon JM, Ren D, Ilyas Kamboh M, Niyonkuru C, Wagner AK: APOE genetic associations with seizure development after severe traumatic brain injury. Brain Inj 2010, 24:1468-1477.
• [17]Briellmann RS, Torn-Broers Y, Busuttil BE, Major BJ, Kalnins RM, Olsen M, Jackson GD, Frauman AG, Berkovic SF: APOE epsilon4 genotype is associated with an earlier onset of chronic temporal lobe epilepsy. Neurology 2000, 55:435-437.
• [18]Brenneman DE, Hill JM, Glazner GW, Gozes I, Phillips TW: Interleukin-1 alpha and vasoactive intestinal peptide: enigmatic regulation of neuronal survival. Int J Dev Neurosci 1995, 13:187-200.
• [19]Rosen DR, Martin-Morris L, Luo LQ, White K: A Drosophila gene encoding a protein resembling the human beta-amyloid protein precursor. Proc Natl Acad Sci USA 1989, 86:2478-2482.
• [20]Ho A, Blum M: Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease. J Neurosci 1998, 18:5614-5629.
• [21]Proper EA, Oestreicher AB, Jansen GH, Veelen CW, van Rijen PC, Gispen WH, de Graan PN: Immunohistochemical characterization of mossy fibre sprouting in the hippocampus of patients with pharmaco-resistant temporal lobe epilepsy. Brain 2000, 123:19-30.
• [22]Lew FH, Buckmaster PS: Is there a critical period for mossy fiber sprouting in a mouse model of temporal lobe epilepsy? Epilepsia 2011, 52:2326-2332.
• [23]Marz W, Scharnagl H, Kirca M, Bohl J, Gross W, Ohm TG: Apolipoprotein E polymorphism is associated with both senile plaque load and Alzheimer-type neurofibrillary tangle formation. Ann N Y Acad Sci 1996, 777:276-280.
• [24]Bernardi S, Scaldaferri N, Vanacore N, Trebbastoni A, Francia A, D'Amico A, Prencipe M: Seizures in Alzheimer's disease: a retrospective study of a cohort of outpatients. Epileptic Disord 2010, 12:16-21.
• [25]Scarmeas N, Honig LS, Choi H, Cantero J, Brandt J, Blacker D, Albert M, Amatniek JC, Marder K, Bell K, Hauser WA, Stern Y: Seizures in Alzheimer disease: who, when, and how common? Arch Neurol 2009, 66:992-997.
• [26]Palop JJ, Mucke L: Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 2009, 66:435-440.